{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:46:48Z","timestamp":1793486808183,"version":"4.5.0"},"reference-count":125,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background\/Objectives: Benign prostatic hyperplasia (BPH) is among the most common conditions affecting men as they age, resulting in lower urinary tract symptoms (LUTS) that can profoundly impact quality of life. While historically attributed primarily to androgenic imbalances, current evidence implicates additional factors\u2014particularly oxidative stress (OS) and chronic inflammation\u2014in BPH pathogenesis. This review aims to synthesize research on the interplay between OS, inflammation, and hormonal regulation in BPH, emphasizing their clinical relevance and potential therapeutic implications. Methods: A comprehensive review of peer-reviewed literature was conducted focusing on mechanistic studies, clinical trials, and observational reports. Searches included data on ROS generation, antioxidant capacity, inflammatory mediators, and their contribution to pathological prostatic overgrowth. Potential interventions targeting OS\u2014such as antioxidant supplementation, anti-inflammatory drugs, vitamin D receptor agonists, and phytotherapeutics\u2014were also evaluated for their efficacy and safety profiles. Results: Chronic inflammation and OS were consistently identified within hyperplastic prostate tissue. Excessive ROS production, diminished antioxidant defense, and sustained cytokine release create a proproliferative and antiapoptotic environment, accelerating disease progression. Metabolic comorbidities (e.g., obesity, insulin resistance) further exacerbate these imbalances. Standard therapies (\u03b1-blockers and 5-ARIs) effectively relieve symptoms but do not directly address the oxidative\u2013inflammatory axis. Emerging evidence suggests that pharmacological and dietary approaches targeting OS and inflammation may reduce prostate volume expansion and alleviate LUTS. Conclusions: Findings indicate that OS and inflammation are key contributors to BPH progression. Incorporating antioxidant and anti-inflammatory strategies alongside conventional treatments holds promise for improving clinical outcomes and patient quality of life. Future research should focus on validating OS-specific biomarkers and optimizing personalized therapy regimens.<\/jats:p>","DOI":"10.3390\/diseases13020053","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:54:06Z","timestamp":1739274846000},"page":"53","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-312X","authenticated-orcid":false,"given":"Aris","family":"Kaltsas","sequence":"first","affiliation":[{"name":"Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoleon","family":"Giannakas","sequence":"additional","affiliation":[{"name":"Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-3308","authenticated-orcid":false,"given":"Zisis","family":"Kratiras","sequence":"additional","affiliation":[{"name":"Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1688-005X","authenticated-orcid":false,"given":"Michael","family":"Chrisofos","sequence":"additional","affiliation":[{"name":"Third Department of Urology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ye, Z., Wang, J., Xiao, Y., Luo, J., Xu, L., and Chen, Z. (2024). Global burden of benign prostatic hyperplasia in males aged 60\u201390 years from 1990 to 2019: Results from the global burden of disease study 2019. BMC Urol., 24.","DOI":"10.1186\/s12894-024-01582-w"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0140-6736(91)90543-X","article-title":"High prevalence of benign prostatic hypertrophy in the community","volume":"338","author":"Garraway","year":"1991","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-4295(03)00045-1","article-title":"The role of dihydrotestosterone in benign prostatic hyperplasia","volume":"61","author":"Carson","year":"2003","journal-title":"Urology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/MOU.0b013e32835abd4a","article-title":"Correlation between benign prostatic hyperplasia and inflammation","volume":"23","author":"Bostanci","year":"2013","journal-title":"Curr. Opin. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.LAB.0000081388.40145.65","article-title":"Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue","volume":"83","author":"Steiner","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.freeradbiomed.2007.03.027","article-title":"Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropy","volume":"43","author":"Lambeth","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1097\/01.ju.0000133655.71782.14","article-title":"Molecular and cellular pathogenesis of benign prostatic hyperplasia","volume":"172","author":"Lee","year":"2004","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/CIRCRESAHA.117.311401","article-title":"Reactive Oxygen Species in Metabolic and Inflammatory Signaling","volume":"122","author":"Forrester","year":"2018","journal-title":"Circ. Res."},{"key":"ref_9","first-page":"147","article-title":"Role of inflammation in benign prostatic hyperplasia","volume":"13","author":"Chughtai","year":"2011","journal-title":"Rev. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/iju.15518","article-title":"Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options","volume":"31","author":"Inamura","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Hu, X., and Zou, L.Q. (2024). Flavonoids as therapeutic agents for epilepsy: Unveiling anti-inflammatory and antioxidant pathways for novel treatments. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1457284"},{"key":"ref_12","unstructured":"GBD 2019 Benign Prostatic Hyperplasia Collaborators (2022). The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev., 3, e754\u2013e776."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajur.2017.06.004","article-title":"Epidemiology of clinical benign prostatic hyperplasia","volume":"4","author":"Lim","year":"2017","journal-title":"Asian J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11884-010-0067-2","article-title":"Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors","volume":"5","author":"Parsons","year":"2010","journal-title":"Curr. Bladder Dysfunct. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lfs.2015.01.023","article-title":"What do we know about phytotherapy of benign prostatic hyperplasia?","volume":"126","author":"Allkanjari","year":"2015","journal-title":"Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.pcan.4500221","article-title":"Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia","volume":"1","author":"Hammarsten","year":"1998","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13046-016-0418-8","article-title":"Oxidative stress in prostate hyperplasia and carcinogenesis","volume":"35","author":"Udensi","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bju.15286","article-title":"The rising worldwide impact of benign prostatic hyperplasia","volume":"127","author":"Launer","year":"2021","journal-title":"BJU Int."},{"key":"ref_19","first-page":"27","article-title":"Anatomy of the prostate and morphogenesis of BPH","volume":"145","author":"McNeal","year":"1984","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_20","first-page":"S3","article-title":"Pathophysiology of benign prostatic hyperplasia in the aging male population","volume":"7","author":"Lepor","year":"2005","journal-title":"Rev. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ajur.2019.10.003","article-title":"The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review","volume":"7","author":"Vickman","year":"2020","journal-title":"Asian J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bju.12118","article-title":"The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH)","volume":"112","author":"Gandaglia","year":"2013","journal-title":"BJU Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.mehy.2007.08.022","article-title":"Chronic inflammation in benign prostatic hyperplasia: Implications for therapy","volume":"70","author":"Wang","year":"2008","journal-title":"Med. Hypotheses"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ajur.2017.05.001","article-title":"Metabolic syndrome and benign prostatic hyperplasia: An update","volume":"4","author":"Ngai","year":"2017","journal-title":"Asian J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/2047-783X-15-S2-120","article-title":"Proinflammatory cytokines Il-6 and TNF-alpha and the development of inflammation in obese subjects","volume":"15","author":"Popko","year":"2010","journal-title":"Eur. J. Med. Res."},{"key":"ref_26","first-page":"1","article-title":"The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer","volume":"5","author":"Elkahwaji","year":"2012","journal-title":"Res. Rep. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/pcan.2015.43","article-title":"Metabolic syndrome, inflammation and lower urinary tract symptoms: Possible translational links","volume":"19","author":"He","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000366210","article-title":"Oxidative stress in benign prostatic hyperplasia: A systematic review","volume":"94","author":"Minciullo","year":"2015","journal-title":"Urol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Oseni, S.O., Naar, C., Pavlovic, M., Asghar, W., Hartmann, J.X., Fields, G.B., Esiobu, N., and Kumi-Diaka, J. (2023). The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer. Cancers, 15.","DOI":"10.3390\/cancers15123110"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Juan, C.A., Perez de la Lastra, J.M., Plou, F.J., and Perez-Lebena, E. (2021). The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094642"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","article-title":"ROS function in redox signaling and oxidative stress","volume":"24","author":"Schieber","year":"2014","journal-title":"Curr. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cyto.2008.05.012","article-title":"The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy","volume":"43","author":"Begley","year":"2008","journal-title":"Cytokine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8416763","DOI":"10.1155\/2017\/8416763","article-title":"Oxidative Stress: Harms and Benefits for Human Health","volume":"2017","author":"Pizzino","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/and.12420","article-title":"Oxidative stress in benign prostate hyperplasia","volume":"48","author":"Zabaiou","year":"2016","journal-title":"Andrologia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0046-8177(96)90396-2","article-title":"Apoptotic versus proliferative activities in human benign prostatic hyperplasia","volume":"27","author":"Kyprianou","year":"1996","journal-title":"Hum. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liu, J., Zhang, J., Fu, X., Yang, S., Li, Y., Liu, J., DiSanto, M.E., Chen, P., and Zhang, X. (2023). The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032870"},{"key":"ref_37","unstructured":"Saker, Z., Tsintsadze, O., Jiqia, I., Managadze, L., and Chkhotua, A. (2015). Importance of apoptosis markers (MDM2, BCL-2 AND Bax) in benign prostatic hyperplasia and prostate cancer. Georgian Med. News, 7\u201314."},{"key":"ref_38","first-page":"1849","article-title":"Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma","volume":"26","author":"Iacopino","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00296825","article-title":"Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates","volume":"21","author":"Claus","year":"1993","journal-title":"Urol. Res."},{"key":"ref_40","first-page":"24","article-title":"Apoptotic signaling pathways: Caspases and stress-activated protein kinases","volume":"35","author":"Cho","year":"2002","journal-title":"J. Biochem. Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1089\/ars.2005.7.472","article-title":"Stress-responsive protein kinases in redox-regulated apoptosis signaling","volume":"7","author":"Matsuzawa","year":"2005","journal-title":"Antioxid. Redox Signal"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/JIR.S275595","article-title":"Reactive Oxygen Species: Drivers of Physiological and Pathological Processes","volume":"13","author":"Checa","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1089\/ars.2006.8.600","article-title":"Apoptosis and aging: Role of p66Shc redox protein","volume":"8","author":"Migliaccio","year":"2006","journal-title":"Antioxid. Redox Signal"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/46311","article-title":"The p66shc adaptor protein controls oxidative stress response and life span in mammals","volume":"402","author":"Migliaccio","year":"1999","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pros.20061","article-title":"Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium","volume":"61","author":"Wang","year":"2004","journal-title":"Prostate"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"149185","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0302-2838(02)00548-1","article-title":"Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis","volume":"43","author":"Gentile","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0074-7696(00)99002-8","article-title":"Growth factors and epithelial-stromal interactions in prostate cancer development","volume":"199","author":"Wong","year":"2000","journal-title":"Int. Rev. Cytol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1210\/en.2005-0942","article-title":"Androgens regulate the immune\/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells","volume":"147","author":"Asirvatham","year":"2006","journal-title":"Endocrinology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2007.11.015","article-title":"Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo","volume":"261","author":"Pathak","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/01.ju.0000116617.32728.ca","article-title":"Oxidative DNA damage in patients with prostate cancer and its response to treatment","volume":"171","author":"Miyake","year":"2004","journal-title":"J. Urol."},{"key":"ref_52","first-page":"G7","article-title":"GSH transport in mitochondria: Defense against TNF-induced oxidative stress and alcohol-induced defect","volume":"273","author":"Kaplowitz","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2002-021015","article-title":"Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia","volume":"88","author":"Tsurusaki","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/pros.10242","article-title":"Expression of ERalpha and ERbeta in prostate cancer","volume":"55","author":"Linja","year":"2003","journal-title":"Prostate"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3349\/ymj.2001.42.4.395","article-title":"Development of rat prostatitis model by oral administration of isoflavone and its characteristics","volume":"42","author":"Kwon","year":"2001","journal-title":"Yonsei Med. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.abb.2004.01.009","article-title":"Dietary influences on endocrine-inflammatory interactions in prostate cancer development","volume":"428","author":"Ho","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1096\/fj.07-9526com","article-title":"Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling","volume":"22","author":"Ricke","year":"2008","journal-title":"FASEB J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.juro.2010.06.022","article-title":"Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer","volume":"184","author":"Smith","year":"2010","journal-title":"J. Urol."},{"key":"ref_59","first-page":"122","article-title":"Chemoprevention of prostate cancer","volume":"13","author":"Thompson","year":"1995","journal-title":"Semin. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/sj.cdd.4400959","article-title":"Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line","volume":"9","author":"Armstrong","year":"2002","journal-title":"Cell Death Differ."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pros.23658","article-title":"The association between local atherosclerosis of the prostatic artery and benign prostatic enlargement in humans: Putative mechanism of chronic ischemia for prostatic enlargement","volume":"78","author":"Haga","year":"2018","journal-title":"Prostate"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/pros.23763","article-title":"The association between local arteriosclerosis of the prostatic arteries and chronic inflammation in human benign prostatic enlargement","volume":"79","author":"Haga","year":"2019","journal-title":"Prostate"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Saito, M., Tsounapi, P., Oikawa, R., Shimizu, S., Honda, M., Sejima, T., Kinoshita, Y., and Tomita, S. (2014). Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci. Rep., 4.","DOI":"10.1038\/srep03822"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/pros.10317","article-title":"Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer","volume":"58","author":"Konig","year":"2004","journal-title":"Prostate"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.eururo.2006.12.011","article-title":"Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?","volume":"51","author":"Kramer","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/jac\/46.2.157","article-title":"Chronic prostatitis-an infectious disease?","volume":"46","author":"Naber","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.exger.2004.12.008","article-title":"Benign prostatic hyperplasia: Age-related tissue-remodeling","volume":"40","author":"Untergasser","year":"2005","journal-title":"Exp. Gerontol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1464-410X.2006.06098.x","article-title":"Definition of at-risk patients: Baseline variables","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1464-410x.2001.02231.x","article-title":"Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma","volume":"88","author":"Baltaci","year":"2001","journal-title":"BJU Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<224::AID-PATH422>3.0.CO;2-K","article-title":"Nitric oxide synthases in normal and benign hyperplastic human prostate: Immunohistochemistry and molecular biology","volume":"189","author":"Gradini","year":"1999","journal-title":"J. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/pros.10020","article-title":"Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate","volume":"49","author":"Handisurya","year":"2001","journal-title":"Prostate"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/pros.20916","article-title":"Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation","volume":"69","author":"Vykhovanets","year":"2009","journal-title":"Prostate"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.4049\/jimmunol.0801875","article-title":"Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation","volume":"182","author":"Penna","year":"2009","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/carcin\/bgp043","article-title":"Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1","volume":"30","author":"Cohen","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/pros.20896","article-title":"The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA\/Rho kinase and NF-kappaB pathways","volume":"69","author":"Penna","year":"2009","journal-title":"Prostate"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/138955707780859431","article-title":"Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy","volume":"7","author":"Sarkar","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2004.09.028","article-title":"Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: Targets for chemopreventive strategies","volume":"41","author":"Pathak","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_78","first-page":"S42","article-title":"The medical therapy of prostatic symptoms study: What will we learn?","volume":"5","author":"Slawin","year":"2003","journal-title":"Rev. Urol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0197-2456(02)00263-5","article-title":"Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial","volume":"24","author":"Bautista","year":"2003","journal-title":"Control Clin. Trials"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/0962935031000097745","article-title":"Malondialdehyde in benign prostate hypertrophy: A useful marker?","volume":"12","author":"Merendino","year":"2003","journal-title":"Mediat. Inflamm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jsbmb.2007.09.013","article-title":"Prostate growth and inflammation","volume":"108","author":"Sciarra","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/pros.20862","article-title":"Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: Preventive effects of celecoxib","volume":"69","author":"Narayanan","year":"2009","journal-title":"Prostate"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eururo.2004.08.024","article-title":"Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)","volume":"47","author":"Bosman","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.20110","article-title":"Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III)","volume":"62","author":"Rohrmann","year":"2005","journal-title":"Prostate"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.eururo.2006.07.016","article-title":"Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis\/chronic pelvic pain syndrome and benign prostatic hyperplasia","volume":"51","author":"Penna","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s10753-009-9121-7","article-title":"The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels","volume":"32","author":"Mechergui","year":"2009","journal-title":"Inflammation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/pros.20051","article-title":"Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia","volume":"60","author":"Castro","year":"2004","journal-title":"Prostate"},{"key":"ref_88","first-page":"2107","article-title":"Impact of total PSA and percent free PSA in the differentiation of prostate disease: A retrospective comparative study implicating neoplastic and non-neoplastic entities","volume":"24","author":"Vezyraki","year":"2019","journal-title":"J. BUON"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11934-008-0056-6","article-title":"Prostate cancer and chronic prostatitis","volume":"9","author":"Sandhu","year":"2008","journal-title":"Curr. Urol. Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis","volume":"7","author":"Platz","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MOU.0b013e3282f9b3b7","article-title":"Inflammation, infection, and prostate cancer","volume":"18","author":"Klein","year":"2008","journal-title":"Curr. Opin. Urol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/01.ju.0000108131.43160.77","article-title":"Epidemiology of inflammation and prostate cancer","volume":"171","author":"Platz","year":"2004","journal-title":"J. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ucl.2007.09.006","article-title":"Inflammation and prostate cancer: A future target for prevention and therapy?","volume":"35","author":"Stock","year":"2008","journal-title":"Urol. Clin. N. Am."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1464-410X.2004.05022.x","article-title":"Pharmacological therapy of benign prostatic hyperplasia\/lower urinary tract symptoms: An overview for the practising clinician","volume":"94","author":"Chapple","year":"2004","journal-title":"BJU Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0090-4295(03)00605-8","article-title":"Diagnosis and treatment of voiding symptoms","volume":"62","author":"Takeda","year":"2003","journal-title":"Urology"},{"key":"ref_96","first-page":"1325","article-title":"Benign prostatic hyperplasia","volume":"70","author":"Webber","year":"2004","journal-title":"Clin. Evid."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/iju.13721","article-title":"Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study","volume":"25","author":"Sakalis","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/iju.15612","article-title":"Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia","volume":"32","author":"Inamura","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Shimizu, S., Shimizu, T., Tsounapi, P., Higashi, Y., Martin, D.T., Nakamura, K., Honda, M., Inoue, K., and Saito, M. (2015). Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133798"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.cej.0000197451.02604.25","article-title":"Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population","volume":"15","author":"Mahmud","year":"2006","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/dji173","article-title":"A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence","volume":"97","author":"Jacobs","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4065\/77.3.219","article-title":"A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer","volume":"77","author":"Roberts","year":"2002","journal-title":"Mayo Clin. Proc."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/carcin\/bgn245","article-title":"COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men","volume":"29","author":"Fernandez","year":"2008","journal-title":"Carcinogenesis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Rasheed, R.A., Sadek, A.S., Khattab, R.T., Elkhamisy, F.A.A., Abdelfattah, H.A., Elshaer, M.M.A., Almutairi, S.M., Hussein, D.S., Embaby, A.S., and Almoatasem, M.A.M. (2023). Diacerein provokes apoptosis, improves redox balance, and downregulates PCNA and TNF-alpha in a rat model of testosterone-induced benign prostatic hyperplasia: A new non-invasive approach. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0293682"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2174\/1381612826666200226121510","article-title":"The Effect of PDE5 Inhibitors on the Male Reproductive Tract","volume":"27","author":"Sofikitis","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(00)00949-3","article-title":"Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer","volume":"57","author":"Fleshner","year":"2001","journal-title":"Urology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.2174\/0929867033456341","article-title":"Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention--a mechanistic approach","volume":"10","author":"Sikka","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2008.862","article-title":"Vitamins E and C in the prevention of prostate and total cancer in men: The Physicians\u2019 Health Study II randomized controlled trial","volume":"301","author":"Gaziano","year":"2009","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Kaltsas, A. (2023). Oxidative Stress and Male Infertility: The Protective Role of Antioxidants. Medicina, 59.","DOI":"10.3390\/medicina59101769"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E","article-title":"Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients","volume":"29","author":"Carraro","year":"1996","journal-title":"Prostate"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002409900098","article-title":"A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens","volume":"28","author":"Levin","year":"2000","journal-title":"Urol. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1464-410X.1996.00104.x","article-title":"Phytotherapy for the prostate","volume":"78","author":"Buck","year":"1996","journal-title":"Br. J. Urol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1097\/01.ju.0000140503.11467.8e","article-title":"Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action","volume":"172","author":"Buck","year":"2004","journal-title":"J. Urol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.abb.2004.04.023","article-title":"Lycopene: Modes of action to promote prostate health","volume":"430","author":"Wertz","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"V74","DOI":"10.1359\/jbmr.07s213","article-title":"Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: Role of anti-inflammatory activity","volume":"22","author":"Krishnan","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.5534\/wjmh.240071","article-title":"The Combination of Curcumae Radix and Syzygium Aromaticum Extracts Mitigates Benign Prostatic Hyperplasia through Anti-Proliferative and Anti-Inflammatory Effects","volume":"42","author":"Lee","year":"2024","journal-title":"World J. Men\u2019s Health"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"42","DOI":"10.15430\/JCP.2022.27.1.42","article-title":"Ethanol Extract of Chaenomeles sinensis Inhibits the Development of Benign Prostatic Hyperplasia by Exhibiting Anti-oxidant and Anti-inflammatory Effects","volume":"27","author":"Kang","year":"2022","journal-title":"J. Cancer Prev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jn\/138.1.49","article-title":"Lycopene inhibits disease progression in patients with benign prostate hyperplasia","volume":"138","author":"Schwarz","year":"2008","journal-title":"J. Nutr."},{"key":"ref_121","first-page":"739","article-title":"Tomato lycopene and its role in human health and chronic diseases","volume":"163","author":"Agarwal","year":"2000","journal-title":"CMAJ"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ba, W., Xu, W., Deng, Z., Zhang, B., Zheng, L., and Li, H. (2023). The Antioxidant and Anti-Inflammatory Effects of the Main Carotenoids from Tomatoes via Nrf2 and NF-kappaB Signaling Pathways. Nutrients, 15.","DOI":"10.3390\/nu15214652"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ekor, M. (2014). The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol., 4.","DOI":"10.3389\/fphar.2013.00177"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.mou.0000193368.91823.1b","article-title":"Could inflammation be a key component in the progression of benign prostatic hyperplasia?","volume":"16","author":"Kramer","year":"2006","journal-title":"Curr. Opin. Urol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.juro.2014.01.114","article-title":"Personalized medicine for the management of benign prostatic hyperplasia","volume":"192","author":"Bechis","year":"2014","journal-title":"J. Urol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/2\/53\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:26Z","timestamp":1760027486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/2\/53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":125,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["diseases13020053"],"URL":"https:\/\/doi.org\/10.3390\/diseases13020053","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]}}}